Federal University of Mato Grosso do Sul   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Campo Grande Brazil (1979)

Organization Overview

First Clinical Trial
2004
NCT00630747
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Federal University of Mato Grosso | Fiocruz Mato Grosso do Sul | Hospital Universitario da Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul | Instituto de Cardiologia/ Fundação Universitária de Cardiologia | Julio Muller University Hospital Federal University of Mato Grosso | Universidade Federal de Mato Grosso do Sul

Active Ingredients

Drugs in Phase 4 Trials (2)

bacille calmette-guerin (1 trial)

isoniazid (nydrazid) (2 trials)

Drugs in Phase 3 Trials (5)

icosapent ethyl (vascepa) (1 trial)

idursulfase (elaprase) (1 trial)

maltodextrin (2 trials)

meglumine antimoniate (1 trial)

miltefosine (impavido) (1 trial)

Drugs in Phase 2 Trials (1)

l-glutamine (1 trial)

Drugs in Other Trials (1)

whey protein (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 3)

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 3)

Mucopolysaccharidoses (Phase 3)

Mucopolysaccharidosis II (Phase 3)

Postoperative Complications (Phase 3)

Proctitis (Phase 3)

Respiratory Aspiration of Gastric Contents (Phase 2)

Syndrome (Phase 3)

Tuberculosis (Phase 4)

Tuberculosis, Pulmonary (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 9